The approval is based on successful trials demonstrating its efficacy and safety, positioning GSK as a leader in addressing type 2 inflammation-related diseases. More about GlaxoSmithKline GSK is ...
Up to 80% of patients with CRSwNP have type 2 inflammation, which is associated with more severe disease and nasal polyp recurrence and can be detected by blood eosinophil count, a biomarker measured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback